当前位置: X-MOL 学术Acta Pharmacol. Sin. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Recent advances in dopaminergic strategies for the treatment of Parkinson's disease.
Acta Pharmacologica Sinica ( IF 6.9 ) Pub Date : 2020-02-28 , DOI: 10.1038/s41401-020-0365-y
Qi Mao 1 , Wang-Zhi Qin 1 , Ao Zhang 2, 3, 4 , Na Ye 1
Affiliation  

Parkinson's disease (PD) is the second most common progressive neurodegenerative disease worldwide. However, there is no available therapy reversing the neurodegenerative process of PD. Based on the loss of dopamine or dopaminergic dysfunction in PD patients, most of the current therapies focus on symptomatic relief to improve patient quality of life. As dopamine replacement treatment remains the most effective symptomatic pharmacotherapy for PD, herein we provide an overview of the current pharmacotherapies, summarize the clinical development status of novel dopaminergic agents, and highlight the challenge and opportunity of emerging preclinical dopaminergic approaches aimed at managing the features and progression of PD.

中文翻译:

多巴胺能疗法治疗帕金森氏病的最新进展。

帕金森氏病(PD)是全球第二大最常见的进行性神经退行性疾病。然而,没有可用的疗法可以逆转PD的神经变性过程。基于PD患者中多巴胺或多巴胺能功能障碍的丧失,当前的大多数疗法集中于症状缓解以改善患者的生活质量。由于多巴胺替代疗法仍然是PD的最有效的对症药物疗法,因此在此我们概述了当前的药物疗法,总结了新型多巴胺能药物的临床发展状况,并着重介绍了旨在管理这些特征和特点的临床前多巴胺能疗法的挑战和机遇。 PD的进展。
更新日期:2020-02-28
down
wechat
bug